CapWealth Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.2M Buy
8,915
+8,534
+2,240% +$8.65M 0.61% 51
2025
Q4
$409K Buy
381
+3
+0.8% +$2.87K 0.03% 99
2025
Q3
$288K Sell
378
-15
-4% -$11.2K 0.02% 103
2025
Q2
$306K Sell
393
-69
-15% -$53.6K 0.03% 88
2025
Q1
$382K Buy
462
+19
+4% +$15.8K 0.04% 79
2024
Q4
$342K Hold
443
0.04% 82
2024
Q3
$392K Buy
443
+5
+1% +$4.5K 0.04% 80
2024
Q2
$397K Buy
438
+15
+4% +$12K 0.05% 71
2024
Q1
$329K Hold
423
0.04% 77
2023
Q4
$247K Hold
423
0.03% 90
2023
Q3
$227K Buy
+423
New +$218K 0.03% 98
2014
Q3
Sell
-300
Closed -$19K 377
2014
Q2
$19K Sell
300
-125
-29% -$7.46K ﹤0.01% 193
2014
Q1
$25K Hold
425
0.01% 179
2013
Q4
$22K Hold
425
0.01% 201
2013
Q3
$21K Hold
425
0.01% 235
2013
Q2
$21K Buy
+425
New +$23.1K 0.01% 221

Other funds holding LLY

CapWealth Advisors's LLY Position: Q1 2026 in Review

CapWealth Advisors increased its Eli Lilly (LLY) stake by 2,240% in Q1 2026, buying an estimated $8.65M and bringing the position to 8,915 shares worth $8.2M. The position accounts for 0.61% of the portfolio, ranked #51.

CapWealth Advisors first reported a position in LLY in Q2 2013 and has held it in 16 quarters since. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • CapWealth Advisors held 8,915 shares of Eli Lilly worth $8.2M as of Q1 2026.
  • CapWealth Advisors bought 8,534 Eli Lilly shares in Q1 2026, an estimated $8.65M.
  • Eli Lilly made up 0.61% of CapWealth Advisors's portfolio in Q1 2026, its #51 holding.
  • CapWealth Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 16 quarters since.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on CapWealth Advisors's 13F filing for Q1 2026, filed 5 May 2026.